Boston Scientific Corporation (BSX)’s Trend Up, Especially After Today’s 52-Week High Milestone

June 12, 2018 - By Marie Mckinney

Boston Scientific Corporation (NYSE:BSX) Logo

Investors sentiment decreased to 0.96 in Q1 2018. Its down 0.38, from 1.34 in 2017Q4. It is negative, as 42 investors sold Boston Scientific Corporation shares while 181 reduced holdings. 60 funds opened positions while 153 raised stakes. 1.18 billion shares or 0.46% less from 1.18 billion shares in 2017Q4 were reported.
Geode Capital Ltd Liability owns 13.87M shares. 1.24M are owned by Cannell Peter B Inc. Wafra Inv Advisory holds 0.41% of its portfolio in Boston Scientific Corporation (NYSE:BSX) for 329,717 shares. Webster National Bank N A accumulated 1,500 shares. Berson Corrado Inv Advisors Ltd Co, New York-based fund reported 29,641 shares. National Bank & Trust Of America Corp De has 8.93 million shares for 0.04% of their portfolio. Hightower Lc accumulated 25,213 shares. 191,522 were reported by Mason Street Advsrs Limited Company. 2.09 million were reported by Manufacturers Life Insur The. Weiss Multi stated it has 45,000 shares. Tekla Capital Ltd Com owns 457,585 shares. Bnp Paribas Asset Management Sa invested in 1.70 million shares. Howe & Rusling reported 65 shares. Oppenheimer & Communications reported 13,968 shares. San Francisco Sentry Inv Grp (Ca) holds 7,152 shares or 0.06% of its portfolio.

Since December 29, 2017, it had 0 insider buys, and 20 selling transactions for $9.49 million activity. Another trade for 1,950 shares valued at $53,496 was made by Sorenson John Bradley on Monday, March 5. $399,865 worth of Boston Scientific Corporation (NYSE:BSX) was sold by Phalen Michael P.. 20,015 shares were sold by Thepaut Eric Francis Yves, worth $603,368. 85,227 Boston Scientific Corporation (NYSE:BSX) shares with value of $2.26 million were sold by Fitzgerald Joseph Michael. 7,500 shares were sold by Butcher Arthur C, worth $225,413 on Thursday, May 10. Ballinger Kevin J. also sold $1.21M worth of Boston Scientific Corporation (NYSE:BSX) on Wednesday, March 14.

The stock of Boston Scientific Corporation (NYSE:BSX) hit a new 52-week high and has $37.04 target or 9.00 % above today’s $33.98 share price. The 8 months bullish chart indicates low risk for the $46.89B company. The 1-year high was reported on Jun, 12 by Barchart.com. If the $37.04 price target is reached, the company will be worth $4.22B more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 0.99% or $0.34 during the last trading session, reaching $33.98. About 9.80 million shares traded or 30.83% up from the average. Boston Scientific Corporation (NYSE:BSX) has risen 11.19% since June 12, 2017 and is uptrending. It has underperformed by 1.38% the S&P500.

Analysts await Boston Scientific Corporation (NYSE:BSX) to report earnings on July, 26. They expect $0.34 earnings per share, up 6.25 % or $0.02 from last year’s $0.32 per share. BSX’s profit will be $469.14 million for 24.99 P/E if the $0.34 EPS becomes a reality. After $0.33 actual earnings per share reported by Boston Scientific Corporation for the previous quarter, Wall Street now forecasts 3.03 % EPS growth.

Boston Scientific Corporation (NYSE:BSX) Ratings Coverage

Among 14 analysts covering Boston Scientific (NYSE:BSX), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. Boston Scientific has $3600 highest and $27 lowest target. $32.93’s average target is -3.09% below currents $33.98 stock price. Boston Scientific had 20 analyst reports since January 3, 2018 according to SRatingsIntel. The rating was maintained by Needham with “Buy” on Thursday, February 1. The stock has “Buy” rating by Citigroup on Tuesday, May 1. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Strong Buy” rating by Raymond James on Thursday, April 26. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Buy” rating by Canaccord Genuity on Wednesday, January 17. Morgan Stanley maintained it with “Overweight” rating and $33 target in Monday, March 19 report. Argus Research maintained the stock with “Buy” rating in Thursday, June 7 report. The company was maintained on Friday, February 2 by Jefferies. Piper Jaffray initiated it with “Buy” rating and $31.0 target in Friday, February 23 report. The company was maintained on Tuesday, January 16 by Needham. The firm earned “Buy” rating on Thursday, April 5 by Bank of America.

More notable recent Boston Scientific Corporation (NYSE:BSX) news were published by: Benzinga.com which released: “32 Stocks Moving In Monday’s Mid-Day Session” on June 11, 2018, also Streetinsider.com with their article: “Wall Street ekes out gains ahead of Singapore summit” published on June 11, 2018, Streetinsider.com published: “JANA Shows New Stakes in Apple (AAPL), Boston Scientific (BSX), Dropbox (DBX), iQIYI (IQ) (more..) -13F” on May 15, 2018. More interesting news about Boston Scientific Corporation (NYSE:BSX) were released by: Streetinsider.com and their article: “Stryker (SYK) Made Takeover Approach for Boston Scientific (BSX) – WSJ” published on June 11, 2018 as well as Streetinsider.com‘s news article titled: “Boston Scientific (BSX) option implied volatility elevated, says won’t comment on ‘market rumors or speculation'” with publication date: June 12, 2018.

Boston Scientific Corporation develops, makes, and markets medical devices for use in various interventional medical specialties worldwide. The company has market cap of $46.89 billion. It operates through three divisions: Cardiovascular, Rhythm Management, and MedSurg. It has a 447.11 P/E ratio. The firm offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Boston Scientific Corporation (NYSE:BSX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.